This site has been produced by Kite, a Gilead Company

Patient Experience

These patients have all received CAR T-cell therapy for non-Hodgkin’s lymphoma (NHL). For patients with other types of blood cancer, their experience is similar. To hear the personal stories of these individuals, click below.

Jacquie

Jacquie received a diagnosis of diffuse large B-cell lymphoma (DLBCL) in 2019. She explains her treatment journey to date, from initial treatment, to finding out she was eligible for CAR T and going through the process of receiving therapy.

Kathy

Kathy was diagnosed with DLBCL in 2019. She explains her journey with CAR T-cell therapy starting from T cell collection to the monitoring and follow-up process of receiving a clear 90-day scan.

Neil

Neil was diagnosed with transformed follicular lymphoma and received news that his initial treatment was unsuccessful. While this was concerning, it opened up new doors for Neil as he was eligible for CAR T-cell therapy.

Alexander

In 2020, Alexander received his DLBCL diagnosis. He explains his CAR T infusion experience and how he has been feeling since receiving treatment.

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet.

United Kingdom: Reporting of side effects

For patients residing in the United Kingdom, you can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. By reporting side effects, you can help provide more information on the safety of your medicine.

Republic of Ireland: Reporting of side effects

For patients residing in the Republic of Ireland, you can also report side effects directly via the HPRA website at www.hpra.ie. By reporting side effects, you can help provide more information on the safety of your medicine.

This site is a patient information resource, intended only for patients residing in the United Kingdom and Ireland who are being referred for or have been prescribed CAR T-cell therapy by their healthcare professional. This site has been developed and paid for by Kite, a Gilead Company.

This site has been produced by Kite, a Gilead Company

© 2023 Gilead Sciences, Inc. All rights reserved. KITE and the Kite logo are registered trademarks of Kite Pharma, Inc | GILEAD is a registered trademark of Gilead Sciences, Inc and its related companies

UK-UNB-3799 April 2023